8900 Glenlyon Parkway
About Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.
October 6, 2005
CEO: Mark Murray
CMO (Medical): Mark Kowalski
CFO: Bruce Cousins
CSO (Scientific): Michael Sofia
CTO: Peter Lutwyche
Please click here for clinical trial information.
403 articles with Arbutus Biopharma
Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics Announce Business Combination to Create New Company Focused on RNAi Delivery and Therapeutics
Tekmira Pharmaceuticals Corporation's Partner Hana Biosciences, Inc. Presents Marqibo(R) Data at American Society of Hematology Meeting
Tekmira Pharmaceuticals Corporation Partner Hana Biosciences, Inc. Achieves Clinical Progress in 2007
Tekmira Pharmaceuticals Corporation Provides Update on Ongoing Legal Dispute With Protiva Biotherapeutics
INEX Pharmaceuticals Announces Completion of Spin-out of Tekmira Pharmaceuticals Corporation and Closed a $5.3 Million Convertible Debenture Financing
INEX Pharmaceuticals Announces Expected Completion Date for Spin-out of Tekmira Pharmaceuticals Corporation
INEX Pharmaceuticals Extends Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
INEX Pharmaceuticals Provides Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
INEX Pharmaceuticals Provides Update On Upcoming Court Hearings And Closing Of Tekmira Pharmaceuticals Corporation Spin-out
INEX Pharmaceuticals Updates Timeline For Completing Spin-Out Of Tekmira Pharmaceuticals Corporation